Vivimed Labs Limited (VIVIMEDLAB) AI Stock Analysis

• Market Cap: ₹576.25M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): -0.28
• Revenue Growth: -22.42%
• EPS Growth: 21.83%
• Country: IN
• Employees: 607
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.88
• Shares Outstanding: 82,913,910
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.04
• Price to Book (P/B): -1.17
• Price to Sales (P/S): 0.35
• P/FCF Ratio: -4.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: ₹8.00 ▲(61.62% Upside)
• Action: Downgraded Date: 01/21/26
• Date: Action: Downgraded 01/21/26

The score is driven primarily by severe financial weakness (declining revenue, collapsing margins, ongoing losses, negative equity, and negative cash flows). Technical indicators also lean bearish with price below key moving averages and a negative MACD. Valuation is not supportive due to the negative P/E and no indicated dividend yield.

Positive Factors

Diversified business mix

Vivimed's exposure to pharmaceuticals, personal care and specialty chemicals provides multiple end markets and revenue channels. This diversification reduces dependence on a single segment, smoothing demand cycles and supporting more resilient revenue streams over a multi‑month horizon.

Vertical manufacturing capabilities

Owning API development and finished-dosage manufacturing creates vertical integration advantages: better control of quality, margins and timelines. That capability supports contract manufacturing and customer retention, strengthening durable competitive positioning in regulated pharma supply chains.

Contract manufacturing and partnerships

Established contract manufacturing relationships and collaborations with major pharma customers provide recurring revenue and higher switching costs. Such B2B agreements can deliver multi‑period revenue visibility and support operational scale even amid end‑market volatility.

Negative Factors

Declining revenue trend

A pronounced top‑line contraction reduces economies of scale and can impair fixed-cost coverage and investment capacity. Persistent revenue declines over successive periods signal weakening market share or demand and can materially constrain recovery prospects without structural changes.

Collapsed gross margins

A dramatic erosion of gross margins suggests sustained pricing pressure, higher input costs, or portfolio mix deterioration. Such margin collapse undermines the firm’s ability to fund R&D, capex and SG&A, making operational recovery harder and leaving profitability vulnerable over months.

Balance sheet and cash flow stress

Persistent negative operating and free cash flows plus steep FCF deterioration constrain liquidity, raise refinancing risk and limit strategic options. With stressed cash generation, the company faces durable solvency pressure that can restrict investment and prolong recovery timelines.

Vivimed Labs Limited Business Overview & Revenue Model

Company Description

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India, Mexico, Spain, Hungary, and internationally. It operates in two segments, Specialty Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also offers a range of hair dye intermediates for use in permanent, semi-permanent, and temporary hair colorant systems; oxidation dye couplers and bases to formulate various permanent and demi-permanent shades; direct dyes for semi-permanent formulations; and basic dyes for temporary, semi-permanent, and color-refresher shampoos and conditioners under the Jarocol name. In addition, the company manufactures and markets photochromic dyes under the Reversacol name; and anti-microbial actives for use in a range of applications, including plastics additives and anti-bacterial handwashes. Further, it offers photographic chemicals, such as black and white developers, and antifog additives for use in medical and industrial X-ray imaging, consumer photography, and litho-plate production for the graphic arts industry. Additionally, the company manufactures Favulous for the treatment of mild to moderate cases of Covid-19. Its products are used in home, personal, and industrial care segments. The company was incorporated in 1988 and is based in Hyderabad, India.

How the Company Makes Money

Vivimed Labs generates revenue primarily through the sale of its pharmaceutical products, which include APIs and finished formulations for various therapeutic segments. Additionally, the company earns income from its specialty chemicals division, which supplies products to the personal care and cosmetics industries, as well as other industrial sectors. Key revenue streams include contract manufacturing partnerships and collaborations with major pharmaceutical companies, enabling Vivimed to leverage its manufacturing capabilities and expertise. The company may also benefit from licensing agreements and export sales in various international markets, contributing to its overall financial performance.

Vivimed Labs Limited Financial Statement Overview

Summary

Very weak fundamentals: revenue declined sharply (most recent revenue growth -18.75%), profitability collapsed (gross margin fell from 58.85% in 2021 to 6.71% in 2025) with ongoing negative net/EBIT/EBITDA margins, the balance sheet shows negative equity and high leverage risk (debt-to-equity -10.70 in 2025), and cash flows are negative with steep free-cash-flow deterioration (FCF growth -145.86% in 2025).

Income Statement

Vivimed Labs Limited has faced significant challenges in its income statement metrics. The company has experienced a consistent decline in revenue over the years, with a notable revenue growth rate of -18.75% in the most recent year. Gross profit margins have deteriorated sharply from 58.85% in 2021 to 6.71% in 2025, indicating a severe decline in profitability. Net profit margins have remained negative, reflecting ongoing losses. The EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and financial distress.

Balance Sheet

The balance sheet of Vivimed Labs Limited reveals a precarious financial position. The company has a negative stockholders' equity in recent years, resulting in an alarming debt-to-equity ratio of -10.70 in 2025. This indicates a high level of financial leverage and potential solvency issues. The return on equity is negative, reflecting the company's inability to generate returns for shareholders. The equity ratio has also been negative, underscoring the company's reliance on debt financing.

Cash Flow

Vivimed Labs Limited's cash flow metrics show significant challenges. The company has experienced negative operating and free cash flows in recent years, with a free cash flow growth rate of -145.86% in 2025. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its losses. The free cash flow to net income ratio is positive, but this is due to the negative net income, which is not a positive indicator of financial health.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	470.02M	1.16B	1.49B	1.87B	2.37B	8.61B
Gross Profit	114.72M	77.98M	705.71M	-928.65M	838.04M	5.07B
EBITDA	18.49M	-86.77M	-246.69M	-1.86B	-67.91M	336.05M
Net Income	-110.93M	-319.61M	-454.46M	-3.29B	-676.50M	-777.95M
Balance Sheet
Total Assets	0.00	9.21B	9.51B	9.88B	12.66B	12.89B
Cash, Cash Equivalents and Short-Term Investments	7.08M	7.08M	717.79M	37.62M	71.84M	64.31M
Total Debt	0.00	3.76B	3.79B	3.81B	2.78B	2.53B
Total Liabilities	351.69M	9.56B	9.56B	9.49B	9.02B	8.58B
Stockholders Equity	-351.69M	-351.69M	-54.61M	394.23M	3.64B	4.32B
Cash Flow
Free Cash Flow	0.00	-86.28M	-260.30M	303.54M	-6.75B	5.67B
Operating Cash Flow	0.00	-40.97M	-239.91M	138.12M	-6.58B	5.67B
Investing Cash Flow	0.00	-45.31M	282.88M	-49.68M	5.23B	4.04B
Financing Cash Flow	0.00	73.10M	-60.32M	-162.44M	-103.80M	-10.15B

Vivimed Labs Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIVIMEDLAB, the sentiment is Negative. The current price of 4.95 is below the 20-day moving average (MA) of 7.37, below the 50-day MA of 9.39, and below the 200-day MA of 6.50, indicating a neutral trend. The MACD of -0.46 indicates Negative momentum. The RSI at 40.54 is Neutral, neither overbought nor oversold. The STOCH value of 13.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIVIMEDLAB.

Vivimed Labs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOFILCHEM	63 Neutral	₹493.42M	172.45	―	―	36.76%	433.63%
BALAXI	62 Neutral	₹1.11B	111.96	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LASA	43 Neutral	₹398.30M	-4.63	―	―	-20.40%	-59.20%
VIVIMEDLAB	39 Underperform	₹576.25M	-1.41	―	―	-22.42%	21.83%